Omalizumab, a monoclonal antibody targeting IgE, has been approved in 2014 for the treatment of H1 antihistamine-refractory chronic urticaria. Data on long-term effectiveness and predictive factors for treatment response are currently limited. In this monocentric, prospective, observational study, 112 patients with chronic spontaneous urticaria (CSU) and 32 patients with chronic inducible urticaria (CIndU) were included. In addition to a rapid response, omalizumab also showed good effectiveness on both forms of chronic urticaria over 2 years. Low total IgE and elevated IgA were identified as potential predictive markers for slower treatment responses in CSU. In conclusion, the present study highlights the efficacy of omalizumab for the treatment of chronic urticaria. With emerging new therapeutic options for chronic urticaria, further genetic as well as molecular markers are needed to establish patient-specific therapy selection.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835204 | PMC |
| http://dx.doi.org/10.5414/ALX02376E | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Eosinophilic dermatitis in a patient with chronic lymphocytic leukemia.
Indian J Pathol Microbiol
January 2025
Department of Medical Oncology, Regional Cancer Centre, Trivandrum, Kerala, India.
Hematological malignancies are known to have cutaneous manifestations, either in the form of direct infiltration of skin by malignant cells or as a result of paraneoplastic syndrome. Many hematological malignancies, including chronic lymphocytic leukemia (CLL), are known to cause malignancy-induced Eosinophilic Dermatoses. We present a case of an elderly woman who presented with multiple pruritic patches.
View Article and Find Full Text PDFClinical and Laboratory Parameters of Metabolic Syndrome in Chronic Spontaneous Urticaria: A Cross-Sectional Study.
Indian Dermatol Online J
December 2024
Department of Dermatology, Venereology, and Leprosy, GSL Medical College and General Hospital, Rajahmahendravaram, Andhra Pradesh, India.
Background: Chronic spontaneous urticaria (CSU) appears to share some pathomechanisms with metabolic syndrome (MS), such as proinflammatory state, increased oxidative stress, changes in adipokine profile, and coagulation system activation.
Aim And Objectives: To evaluate clinical and laboratory parameters of MS in CSU patients and to assess relationship of MS with duration and severity of CSU, Ig-E, thyroid-stimulating hormone (TSH), C-reactive protein (CRP), and autologous serum skin test (ASST).
Materials And Methods: A hospital-based cross-sectional study was conducted on 131 CSU cases and 131 controls who were age- and sex-matched.
Utility of serum biomarkers in real-world practice for predicting response to omalizumab therapy in patients with chronic spontaneous urticaria.
J Allergy Clin Immunol Glob
February 2025
Department of Internal Medicine, Division of Rheumatology, Allergy and Immunology, Cincinnati, Ohio.
Background: Omalizumab (OMA), a recombinant humanized IgG monoclonal anti-IgE antibody, is approved for treatment for chronic spontaneous urticaria (CSU) refractory to second-generation H-antihistamine (SGAH) therapy. However, currently, there are no validated serum biomarkers to reliably predict response to OMA treatment.
Objective: We explored the real-world clinical utility of using serum biomarkers for predicting response to OMA for CSU patients with disease refractory to high-dose SGAH therapy.
Factors associated with quality of life of chronic spontaneous urticaria patients in a Vietnamese population.
PLoS One
January 2025
Department of Dermatology, Hanoi Medical University, Hanoi, Vietnam.
Objective: Chronic spontaneous urticaria (CSU) is a challenging condition that significantly impacts the affected patients. This study aimed to evaluate the quality of life (QoL) among patients with CSU in Vietnam and identify factors associated with QoL.
Methods: A cross-sectional study was conducted at the Vietnam National Dermatology and Venereology Hospital from June 2023 to March 2024.
NOD-like receptor family pyrin domain containing 3 (rs10754558) gene polymorphism in chronic spontaneous urticaria: A pilot case-control study.
Immunobiology
January 2025
Department of Internal Medicine / Allergy and Clinical Immunology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. Electronic address:
Background: Chronic spontaneous urticaria (CSU) is a persistent skin condition with no known cause or trigger. The unpredictability of CSU attacks lowers patients' quality of life. NOD-like receptor pyrin domain containing 3 (NLRP3) gene dysregulation can result in numerous immunological and inflammatory diseases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!